Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Filgrastim + mRNA plus lysate-loaded dendritic cell vaccine + Paclitaxel + Peg-interferon alfa-2a |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Filgrastim | Neupogen | G-CSF | Neupogen (filgrastim) is a recombinant analog of granulocyte colony-stimulating factor (G-CSF) isoform B, which binds and activates G-CSF receptors modulating neutrophilic granulocyte progenitor activity, production, and differentiation (NCI Drug Dictionary). | |
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Peg-interferon alfa-2a | Pegasys | peginterferon alfa-2a|pegylated interferon alfa-2a|PEG-IFNA2a | Pegasys (peg-interferon alfa-2a) comprises interferon alfa-2a conjugated to polyethylene glycol (PEG), which may decrease tumor cell proliferation and enhance anti-tumor immune response (NCI Drug Dictionary). | |
mRNA plus lysate-loaded dendritic cell vaccine | Limited information is currently available on mRNA plus lysate-loaded dendritic cell vaccine, a putative autologous dendritic cell vaccine loaded with mRNA and tumor lysate (Jul 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05799612 | Phase I | Filgrastim + mRNA plus lysate-loaded dendritic cell vaccine + Paclitaxel + Peg-interferon alfa-2a | Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma | Withdrawn | 0 |